Tuning metabolism in liver organoids

An Alnylam-MIT collaboration has used RNAi technology to tune enzyme expression in hepatocyte-based organoids to better model drug metabolism during tox screens.

The collaboration with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) built on a series of papers by Sangeeta Bhatia and colleagues at the Massachusetts Institute of Technology, who developed organoids made from human hepatocyte-based organoids that predicted hepatotoxicity in a panel of approved and preclinical small molecules. Bhatia is a professor of health sciences and technology, electrical engineering and computer science at MIT...